Autoantibodies Against TRPM1 in Patients with Paraneoplastic Retinopathy
Author Information
Author(s): Kondo Mineo, Sanuki Rikako, Ueno Shinji, Nishizawa Yuji, Hashimoto Naozumi, Ohguro Hiroshi, Yamamoto Shuichi, Machida Shigeki, Terasaki Hiroko, Adamus Grazyna, Furukawa Takahisa
Primary Institution: Nagoya University Graduate School of Medicine
Hypothesis
Are there autoantibodies against TRPM1 in the sera of patients with paraneoplastic retinopathy exhibiting ON bipolar cell dysfunction?
Conclusion
The study reveals that TRPM1 is targeted by autoantibodies in some patients with cancer-associated retinopathy or melanoma-associated retinopathy linked to retinal ON bipolar cell dysfunction.
Supporting Evidence
- Two patients with melanoma-associated retinopathy were found to have autoantibodies against TRPM1.
- The study identified TRPM1 as a target for autoantibodies in patients with paraneoplastic retinopathy.
- The presence of TRPM1 autoantibodies was confirmed through Western blot analysis.
Takeaway
Some people with certain types of eye problems related to cancer have antibodies that attack a specific protein in their eyes, which can cause vision issues.
Methodology
Western blot analysis was performed to identify autoantibodies against TRPM1 in the serum of patients with paraneoplastic retinopathy.
Limitations
Limited clinical information was available for two MAR patients associated with TRPM1 autoantibodies.
Participant Demographics
One CAR patient with lung cancer and 26 MAR patients, including a 76-year-old man and a 57-year-old man with histories of skin melanoma.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website